凯莱英盘中跌逾6%，股价创逾3个月新低，Q3净利同比降13.46%。 ...

Group 1 - Key Point 1: As of October 30, 2025, a total of 42 institutional investors disclosed holdings in Kailaiying A-shares, with a total holding of 174 million shares, accounting for 48.14% of Kailaiying's total share capital [1] - Key Point 2: The top ten institutional investors collectively hold 46.97% of Kailaiying's shares, with a decrease of 1.46 percentage points compared to the previous quarter [1] Group 2 - Key Point 1: In the current period, 10 public funds increased their holdings, with a total increase ratio of 0.15%, including major funds like Morgan Stanley Health Industry Mixed A and Southern Medical Health Flexible Allocation Mixed A [2] - Key Point 2: 14 public funds decreased their holdings, with a total decrease ratio of 0.56%, including funds such as Huabao CSI Medical ETF and Southern CSI 500 ETF [2] - Key Point 3: 12 new public funds were disclosed in the current period, including Guangfa Shengjin Mixed A and Huatai-PB Medical Health A [2] - Key Point 4: 493 public funds were not disclosed in the current period, including funds like Fortune Tianhui Growth Mixed (LOF) A/B and Southern CSI 500 ETF [2] Group 3 - Key Point 1: One foreign fund increased its holdings, specifically Hong Kong Central Clearing Limited, with an increase ratio of 0.17% [3] - Key Point 2: One new foreign institution was disclosed, namely ASYMCHEM LABORATORIES, INCORPORATED [3] - Key Point 3: ASYMCHEM LABORATORIES, INCORPORATED was not disclosed in the previous quarter [3]

Group 1 - The core point of the news is that Kailaiying's stock price dropped by 5.2% to 97.20 CNY per share, with a trading volume of 260 million CNY and a turnover rate of 0.84%, resulting in a total market capitalization of 35.05 billion CNY [1] - Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd. is located in Tianjin Economic and Technological Development Zone and was established on October 7, 1998, with its listing date on November 18, 2016 [1] - The company's main business involves providing CMO pharmaceutical outsourcing services, with revenue composition being 76.19% from small molecule CDMO solutions, 23.71% from emerging services, and 0.10% from other sources [1] Group 2 - From the perspective of fund holdings, Guotou Ruijin Fund has one fund heavily invested in Kailaiying, specifically the Guotou Ruijin Healthcare Mixed A Fund (000523), which held 40,700 shares in the third quarter, accounting for 3.21% of the fund's net value, ranking as the seventh largest holding [2] - The Guotou Ruijin Healthcare Mixed A Fund (000523) was established on February 25, 2014, with a latest scale of 129 million CNY, and has achieved a year-to-date return of 33.75%, ranking 2696 out of 8154 in its category [2] - The fund manager, Liu Zexu, has been in position for 2 years and 51 days, with a total asset scale of 243 million CNY, achieving a best return of 29.7% and a worst return of 19.71% during his tenure [2]

格隆汇10月31日丨根据联交所最新权益披露资料显示，2025年10月27日，凯莱英(06821.HK)获Norges Bank在场内以每股均价89.7083港元增持13.22万股，涉 资约1185.94万港元。 | 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 股份數目 | | | (請參閱上述*註 | 有投票權股 (日 / 月 / 年) | | | | | | | | | 份自分玩 | | CS20251028E00493 | Norges Bank | 1101(L) | | 132,200(L | HKD 89.7083 | 3.373.400(L) | 12.24(L)27/10/2025 | | 股份代號: | | --- | | 上市法國名稱: | | 日期 (日 / 月 / 年): | 增持后，Norges Bank最新持股数目为337.34万股，持股比例由1 ...

智通财经APP讯，凯莱英(002821.SZ)发布2025年三季度报告，该公司前三季度营业收入为46.3亿元，同 比增长11.82%。归属于上市公司股东的净利润为8亿元，同比增长12.66%。归属于上市公司股东的扣除 非经常性损益的净利润为7.28亿元，同比增长9.74%。基本每股收益为2.18元。 ...

智通财经APP讯，凯莱英(06821)发布公告，于2025年前三季度，该集团取得营业收入46.3亿元，同比增 加11.82%;归属于上市公司股东的净利润8亿元，同比增加12.66%;基本每股收益2.18元。 公告称，2025 年前三季度，公司实现营业总收入人民币46.3亿元，同比增长11.82%;其中小分子业务收 入基本持平，新兴业务收入同比增长71.87%，化学大分子业务收入同比增长超过150%;来自大制药公司 收入人民币20.53亿元，同比增长1.98%，来自中小制药公司收入人民币25.77亿元，同比增长21.14%。 从下半年待交付的订单分布看，第四季度交付规模将显着高于第三季度，预计全年营业收入将实现 13%-15%增长。 ...

香港联交所最新数据显示，10月27日，Norges Bank增持凯莱英（002821）(06821)13.22万股，每股作价 89.7083港元，总金额约为1185.94万港元。增持后最新持股数目为337.34万股，持股比例为12.24%。 ...

智通财经APP获悉，香港联交所最新数据显示，10月27日，Norges Bank增持凯莱英(06821)13.22万股， 每股作价89.7083港元，总金额约为1185.94万港元。增持后最新持股数目为337.34万股，持股比例为 12.24%。 ...

格隆汇10月30日丨凯莱英(06821.HK)公布2025年第三季度报告。营收约为人民币14.42亿元，同比下降 0.09%。净利润约为1.83亿元，同比下降13.46%。基本每股收益为0.5元。 前三季度营收约为46.3亿元，同比上升11.82%。净利润约为8亿元，同比上升12.66%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，二零二五年十月三十日 於本公告日期，本公司董事會由董事長兼執行董事 Hao Hong 博士，執行董事楊蕊女士 、張達先生及洪亮先生，非執行董事 Ye Song 博士及張婷女士，以及獨立非執行董事孫 雪嬌博士、侯欣一博士及謝維愷先生組成。 凯莱英医药集团（天津）股份有限公司 2025 年第三季度报告 证券代码：002821 证券简称：凯莱英 公告编 ...